Lowest Price Guaranteed From USD 4,899
Published
July 2020
Pages
339
View Count
7520
 |
 |
 |
 |
 |
 |
 |
Over the years, advances in cell biology and pharmacology have led to the development of a variety of advanced biologics, which experts believe, possess the potential to address several unmet needs associated with the treatment of different types of diseases. Currently, there are more than 1,000 cell and gene therapies under development; most of which are being developed for the treatment of oncological disorders, cardiovascular disorders and neurological disorders. Additionally, over the last decade, multiple immunotherapies have been developed, and have led to a decrease in lung cancer and melanoma-related mortality. Despite their many benefits, biologics present a number of challenges, such as drug delivery related complexities, and immunogenicity concerns, which have been shown to result in systemic toxicity post therapy administration. To avoid such systemic toxic effects, a limited volume of drug is administered, which often results in a small amount of drug reaching the target organ. Further, from a pharmacological point of view, the drug stays at the target site for a limited time, hence decreasing the final therapeutic effect that can be achieved through prolonged and controlled drug delivery. Moreover, some of such treatment options, such as cell therapies, require periodic administration of additional therapy material, or complementary products, thereby, adding to the already complex invasive dosing procedure.
In order to address some of the abovementioned challenges, a number of innovator companies in the biopharmaceutical sector are actively engaged in identifying targeted and effective delivery strategies for biologics, including gene therapies, cell / stem cell therapies, immunotherapies and therapeutic proteins. Examples of devices designed for the targeted delivery of biologics include (in alphabetic order, no selection criteria) Advance® CS, ExtroducerTM microcatheter, HelixTM biotherapeutic delivery system, ImmunoPulse® IL-12, SmartFlow® neuro ventricular cannula and MailPan®. Some of the aforementioned drug delivery devices have been demonstrated to have an improved therapeutic safety index, and are capable of accurately delivering biological interventions to the target physiological site. Further, certain implantable delivery systems have also been developed in order to prolong the therapeutic effect of biologics. Given the rapid pace of growth within the biopharmaceutical market, the demand for effective delivery systems is anticipated to increase in the foreseen future. This may be expected to create lucrative opportunities for stakeholders in the targeted drug delivery systems market.
The ‘Organ-based / Targeted Drug Delivery Devices Market for Biologics (Intra-organ / Intra-tumoral), 2020-2030’ report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of such medical devices, over the next decade. The study features an in-depth analysis of the key drivers and trends related to this domain. Amongst other elements, the report includes:
One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as target patient population, likely adoption rates and expected pricing, we have provided an informed estimate of the likely evolution of the market, for the time period 2020-2030. Our year-wise projections for the current and future opportunity have further been segmented on the basis of [A] type of device (encapsulation based delivery device, catheter, electroporation delivery system, and cannula), [B] target organ (brain, heart, breast, eye, skin and pancreas), [C] target therapeutic area (oncological disorders, neurological disorders, cardiovascular disorders, metabolic disorders and ophthalmic diseases), [D] target indication (Parkinson's disease, heart failure, breast cancer, melanoma, glioblastoma, myocardial ischemia, geographic atrophy, glaucoma, macular telangectasia, retinitis pigmentosa, non-infectious uveitis and mucopolysaccharidosis type III A) and [E] key geographical regions (North America, Europe and Asia-Pacific). To account for the uncertainties associated with the development of the devices and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:
All actual figures have been sourced and analysed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Key Questions Answered
Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the likely evolution of the medical devices that are capable of targeted delivery of biologics market in the mid to long-term.
Chapter 3 provides a general overview of drug delivery devices for biologics, focusing on the different routes of administration and the challenges associated with these delivery devices. The chapter also highlights the need for the development of targeted delivery devices for biologics. In addition, it presents the information on the different types of these targeted devices, the key advantages offered and a section on concluding remarks.
Chapter 4 provides a detailed assessment of the companies involved in the development of targeted delivery devices for biologics, providing information and analyses based on a number of relevant parameters, such as type of device (encapsulation based delivery device, catheter, implant, electroporation delivery system, balloon, cannula and microrobot), status of development (approved, clinical and preclinical), target organ (brain, heart, abdomen, breast, eye, and others), target indication (Parkinson's disease, heart failure, diabetes, breast cancer, myocardial infarction, Alzheimer’s, solid tumors (specific type unknown), and others), target therapeutic area (oncological disorders, neurological disorders, cardiovascular disorders, metabolic disorders and ophthalmic diseases), type of biologic delivered (cells, proteins, antibodies, enzymes, plasmids, growth factors, small peptides, neurotransmitters and modified RNA), type of therapy delivered (gene therapy, stem cell therapy, cell therapy, immunotherapy and RNA therapeutics) and route of administration (intra-tumoral, implantable, intraocular, intraputamen, intra-abdominal, intracardiac and others). In addition, the chapter includes information on the device developers, including details on type of stakeholder (industry and non-industry), year of establishment, company size (only for industry players) and location of headquarters.
Chapter 5 features elaborate profiles of devices that are currently approved or being evaluated in later stages of clinical development (phase III and above), featuring an overview of the device, its mechanism of action, current development status and key clinical trial results.
Chapter 6 features an elaborate assessment of the research activity in the neurological and cardiovascular disorders domain, in terms of the development of stem cell and gene therapies for the treatment these disorders. The chapter provides information and analysis on the recent publications and grants that are focused on the stem cell and gene therapies being developed for these therapeutic areas, since 2015.
Chapter 7 features a geographical clinical trial analysis of completed, ongoing and planned studies of various stem cell and gene therapies, based on various parameters, such as trial registration year, trial phase, trial status, type of sponsor / collaborator, type of therapy, therapeutic area, target indication, route of administration, key players, geographical location and enrolled patient population.
Chapter 8 features an analysis presenting the potential strategic partners (primarily stem cell and gene therapy developers) for targeted drug delivery device developers, based on different parameters, such as pipeline strength, target therapeutic area(s) and location of the headquarters of the company.
Chapter 9 presents a comprehensive market forecast analysis, highlighting the likely growth of the targeted drug delivery devices market for biologics, for the time period 2020-2030. In order to provide an informed future outlook, our projections have been segmented on the basis of [A] type of device (encapsulation based delivery device, catheter, electroporation delivery system, and cannula), [B] target organ (brain, heart, breast, eye, skin and pancreas), [C] target therapeutic area (oncological disorders, neurological disorders, cardiovascular disorders, metabolic disorders and ophthalmic diseases), [D] target indication (Parkinson's disease, heart failure, breast cancer, melanoma, glioblastoma, myocardial ischemia, geographic atrophy, glaucoma, macular telangectasia, retinitis pigmentosa, non-infectious uveitis and mucopolysaccharidosis type III A) and [E] key geographical regions (North America, Europe and Asia-Pacific). To account for the uncertainties associated with the development of the devices and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
Chapter 10 summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.
Chapter 11 contains the transcripts of interviews conducted with representatives from renowned organizations that are engaged in this domain. In this study, we spoke to William L Rust (Founder and Chief Executive Officer, Seraxis), Manuel Pires (Junior Business Developer, Defymed), R. Lyle Hood (Assistant Professor, University of Texas at San Antonio) and Anonymous (Postdoctoral Associate, Massachusetts Institute of Technology)
Chapter 12 is an appendix that contains tabulated data and numbers for all the figures provided in the report.
Chapter 13 is an appendix that provides the list of companies and organizations mentioned in the report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4 Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Drug Delivery Devices for Biologics
3.3. Routes of Drug Administration
3.4. Challenges Associated with Drug Delivery of Biologics
3.5. Need for Targeted Drug Delivery
3.6. Devices for Targeted Delivery of Biologics
3.6.1. Types of Devices
3.6.2. Key Advantages
3.7. Concluding Remarks
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Targeted Drug Delivery Devices for Biologics: Overall Market Landscape
4.2.1. Analysis by Type of Device
4.2.2. Analysis by Status of Development
4.2.3. Analysis by Target Organ
4.2.4. Analysis by Target Indication
4.2.5. Analysis by Target Therapeutic Area
4.2.6. Analysis by Type of Biologic Delivered
4.2.7. Analysis by Type of Therapy Delivered
4.2.8. Analysis by Route of Administration
4.3. Targeted Drug Delivery Devices for Biologics: Additional Information
4.4. Targeted Drug Delivery Devices for Biologics: List of Developers
4.4.1. Analysis by Type of Stakeholder
4.4.2. Analysis by Year of Establishment
4.4.3. Analysis by Company Size
4.4.4. Analysis by Location of Headquarters
5. DEVICE PROFILES
5.1. Chapter Overview
5.2. Alcyone MEMS Cannula (AMCTM)
5.2.1. Device Overview
5.2.2. Key Development Highlights
5.2.3. Key Clinical Trial Results
5.3. Bullfrog® Micro-Infusion Device
5.3.1. Device Overview
5.3.2. Key Development Highlights
5.3.3. Key Clinical Trial Results
5.4. HelixTM Biotherapeutic Delivery System
5.4.1. Device Overview
5.4.2. Key Development Highlights
5.4.3. Key Clinical Trial Results
5.5. Orbit Subretinal Delivery System
5.5.1. Device Overview
5.5.2. Key Development Highlights
5.5.3. Key Clinical Trial Results
5.6. SmartFlow® Neuro Ventricular Cannula
5.6.1. Device Overview
5.6.2. Key Development Highlights
5.6.3. Key Clinical Trial Results
5.7. Renexus®
5.7.1. Device Overview
5.7.2. Key Development Highlights
5.7.3. Key Clinical Trial Results
6. PROMISING THERAPEUTIC AREAS
6.1. Chapter Overview
6.2. Neurological Disorders
6.2.1. Stem Cell Therapies
6.2.1.1. Publication Analysis
6.2.1.1.1. Methodology
6.2.1.1.2. List of Publications
6.2.1.1.3. Analysis by Number of Publications
6.2.1.2. Grant Analysis
6.2.1.2.1. Methodology
6.2.1.2.2. List of Academic Grants
6.2.1.2.3. Analysis by Number of Grants
6.2.1.2.4. Analysis by Grant Amount
6.2.2. Gene Therapies
6.2.2.1. Publication Analysis
6.2.2.1.1. Methodology
6.2.2.1.2. List of Publications
6.2.2.1.3. Analysis by Number of Publications
6.2.2.2. Grant Analysis
6.2.2.2.1. Methodology
6.2.2.2.2. List of Academic Grants
6.2.2.2.3. Analysis by Number of Grants
6.2.2.2.4. Analysis by Grant Amount
6.3. Cardiovascular Disorders
6.3.1. Stem Cell Therapies
6.3.1.1. Publication Analysis
6.3.1.1.1. Methodology
6.3.1.1.2. List of Publications
6.3.1.1.3. Analysis by Number of Publications
6.3.1.2. Grant Analysis
6.3.1.2.1. Methodology
6.3.1.2.2. List of Academic Grants
6.3.1.2.3. Analysis by Number of Grants
6.3.1.2.4. Analysis by Grant Amount
6.3.2. Gene Therapies
6.3.2.1. Publication Analysis
6.3.2.1.1. Methodology
6.3.2.1.2. List of Publications
6.3.2.1.3. Analysis by Number of Publications
6.3.2.2. Grant Analysis
6.3.2.2.1. Methodology
6.3.2.2.2. List of Academic Grants
6.3.2.2.3. Analysis by Number of Grants
6.3.2.2.4. Analysis by Grant Amount
6.3. Summary of R&D Activity
7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Stem Cell and Gene Therapies: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Phase
7.3.3. Analysis by Trial Status
7.3.4. Analysis by Type of Sponsor / Collaborator
7.3.5. Analysis by Type of Therapy
7.3.6. Analysis by Therapeutic Area
7.3.7. Analysis by Therapeutic Indication
7.3.8. Analysis by Route of Administration
7.3.9. Analysis by Trial Status and Trial Phase
7.3.10. Most Active Industry Players: Analysis by Number of Registered Stem Cell and Gene Therapy Clinical Trials
7.3.11. Most Active Non-Industry Players: Analysis by Number of Registered Stem Cell and Gene Therapy Clinical Trials
7.3.12. Analysis by Geographical Location
7.3.13. Analysis by Geographical Location and Trial Phase
7.3.14. Analysis by Geographical Location and Trial Status
7.3.15. Analysis by Geographical Location and Therapeutic Area
7.3.16. Analysis by Patients Enrolled and Trial Registration Year
7.3.17. Analysis by Patients Enrolled and Trial Phase
7.3.18. Analysis by Patients Enrolled and Type of Therapy
7.3.19. Analysis by Patients Enrolled and Therapeutic Area
7.3.20. Analysis by Patients Enrolled, Trial Status and Geographical Location
7.4. Stem Cell Therapies: Clinical Trial Analysis
7.4.1. Analysis by Trial Registration Year
7.4.2. Analysis by Trial Phase
7.4.3. Analysis by Trial Status
7.4.4. Analysis by Type of Sponsor / Collaborator
7.4.5. Analysis by Therapeutic Area
7.4.6. Analysis by Therapeutic Indication
7.4.7. Analysis by Route of Administration
7.4.8. Analysis by Trial Status and Trial Phase
7.4.9. Analysis by Geographical Location
7.4.10. Analysis by Geographical Location and Trial Phase
7.4.11. Analysis by Geographical Location and Trial Status
7.4.12. Analysis by Geographical Location and Therapeutic Area
7.4.13. Analysis by Patients Enrolled and Trial Registration Year
7.4.14. Analysis by Patients Enrolled and Trial Phase
7.4.15. Analysis by Patients Enrolled and Therapeutic Area
7.4.16. Analysis by Patients Enrolled, Trial Status and Geographical Location
7.5. Gene Therapies: Clinical Trial Analysis
7.5.1. Analysis by Trial Registration Year
7.5.2. Analysis by Trial Phase
7.5.3. Analysis by Trial Status
7.5.4. Analysis by Type of Sponsor / Collaborator
7.5.5. Analysis by Therapeutic Area
7.5.6. Analysis by Therapeutic Indication
7.5.7. Analysis by Route of Administration
7.5.8. Analysis by Trial Status and Trial Phase
7.5.9. Analysis by Geographical Location
7.5.10. Analysis by Geographical Location and Trial Phase
7.5.11. Analysis by Geographical Location and Trial Status
7.5.12. Analysis by Geographical Location and Therapeutic Area
7.5.13. Analysis by Patients Enrolled and Trial Registration Year
7.5.14. Analysis by Patients Enrolled and Trial Phase
7.5.15. Analysis by Patients Enrolled and Therapeutic Area
7.5.16. Analysis by Patients Enrolled, Trial Status and Geographical Location
8. LIKELY PARTNER ANALYSIS
8.1. Chapter Overview
8.2. Methodology and Key Parameters
8.3. Stem Cell Therapy Developers: Likely Partners for Device Developers
8.3.1. Opportunities in North America
8.3.1.1. Most Likely Partners
8.3.1.2. Likely Partners
8.3.1.3. Less Likely Partners
8.3.2. Opportunities in Europe
8.3.2.1. Most Likely Partners
8.3.2.2. Likely Partners
8.3.2.3. Less Likely Partners
8.3.3. Opportunities in Asia-Pacific and Rest of the World
8.3.3.1. Most Likely Partners
8.3.3.2. Likely Partners
8.3.3.3. Less Likely Partners
8.4. Gene Therapy Developers: Likely Partner for Device Developers
8.4.1. Opportunities in North America
8.4.1.1. Most Likely Partners
8.4.1.2. Likely Partners
8.4.1.3. Less Likely Partners
8.4.2. Opportunities in Europe
8.4.2.1. Most Likely Partners
8.4.2.2. Likely Partners
8.4.2.3. Less Likely Partners
8.4.3. Opportunities in Asia-Pacific and Rest of the World
8.4.3.1. Most Likely Partners
8.4.3.2. Likely Partners
8.4.3.3. Less Likely Partners
9. MARKET FORECAST
9.1. Chapter Overview
9.2. Forecast Methodology and Key Assumptions
9.3. Targeted Drug Delivery Devices Market for Biologics, Till 2030
9.4. Targeted Drug Delivery Devices Market for Biologics: Individual Drug Device Combination Product Sales Forecasts
9.4.1. BCDA-01 and HelixTM Biotherapeutic Delivery System
9.4.1.1. Target Patient Population
9.4.1.2. Device Forecast by Number of units
9.4.1.3. Sales Forecast
9.4.2. BCDA-02 and HelixTM Biotherapeutic Delivery System
9.4.2.1. Target Patient Population
9.4.2.2. Device Forecast by Number of units
9.4.2.3. Sales Forecast
9.4.3. Renexus®
9.4.3.1. Target Patient Population
9.4.3.2. Sales Forecast
9.4.4. LYS-SAF302 and SmartFlow® Neuro Ventricular Cannula
9.4.4.1. Target Patient Population
9.4.4.2. Device Forecast by Number of units
9.4.4.3. Sales Forecast
9.4.5. Cell-in-a-Box®
9.4.5.1. Target Patient Population
9.4.5.2. Sales Forecast
9.4.6. DNX-2401 and Alcyone's MEMS Cannula
9.4.6.1. Target Patient Population
9.4.6.2. Device Forecast by Number of units
9.4.6.3. Sales Forecast
9.4.7. EYS606 and Electro-Transfection Injection System
9.4.7.1. Target Patient Population
9.4.7.2. Device Forecast by Number of units
9.4.7.3. Sales Forecast
9.4.8. NTCELL®
9.4.8.1. Target Patient Population
9.4.8.2. Sales Forecast
9.4.9. TAVO and ImmunoPulse® IL-12
9.4.9.1. Target Patient Population
9.4.9.2. Device Forecast by Number of units
9.4.9.3. Sales Forecast
9.4.10. VY-AADC02 and SmartFlow® Neuro Ventricular Cannula
9.4.10.1. Target Patient Population
9.4.10.2. Device Forecast by Number of units
9.4.10.3. Sales Forecast
9.5. Targeted Drug Delivery Devices Market for Biologics: Distribution by Type of Device, Till 2030
9.6. Targeted Drug Delivery Devices Market for Biologics: Distribution by Target Organ, Till 2030
9.7. Targeted Drug Delivery Devices Market for Biologics: Distribution by Target Indication, Till 2030
9.8. Targeted Drug Delivery Devices Market for Biologics: Distribution by Target Therapeutic Area, Till 2030
9.9. Targeted Drug Delivery Devices Market for Biologics: Distribution by Type of Therapy Delivered, Till 2030
9.10. Targeted Drug Delivery Devices Market for Biologics: Distribution by Key Geographical Regions, Till 2030
9.10.1. Targeted Drug Delivery Devices Market for Biologics in North America, Till 2030
9.10.2. Targeted Drug Delivery Devices Market for Biologics in Europe, Till 2030
9.10.3. Targeted Drug Delivery Devices Market for Biologics in Asia-Pacific, Till 2030
10. CONCLUDING REMARKS
10.1. Chapter Overview
11. EXECUTIVE INSIGHTS
11.1. Chapter Overview
11.2. Seraxis
11.2.1. Company Snapshot
11.2.2. Interview Transcript: William L Rust, Founder and Chief Executive Officer
11.3. Defymed
11.3.1. Company Snapshot
11.3.2. Interview Transcript: Manuel Pires, Junior Business Developer
11.4. University of Texas at San Antonio
11.4.1. Organization Snapshot
11.4.2. Interview Transcript: R. Lyle Hood, Assistant Professor
11.5. Massachusetts Institute of Technology
11.5.1. Organization Snapshot
11.5.2. Interview Transcript: Anonymous, Postdoctoral Associate
12. APPENDIX 1: TABULATED DATA
13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Drug Delivery Devices for Biologics
Figure 3.2 Routes of Drug Administration
Figure 4.1 Targeted Drug Delivery Devices for Biologics: Distribution by Type of Device
Figure 4.2 Targeted Drug Delivery Devices for Biologics: Distribution by Status of Development
Figure 4.3 Targeted Drug Delivery Devices for Biologics: Distribution by Type of Device and Status of Development
Figure 4.4 Targeted Drug Delivery Devices for Biologics: Distribution by Target Organ
Figure 4.5 Targeted Drug Delivery Devices for Biologics: Distribution by Type of Device and Target Organ
Figure 4.6 Targeted Drug Delivery Devices for Biologics: Distribution by Target Indication
Figure 4.7 Targeted Drug Delivery Devices for Biologics: Distribution by Target Therapeutic Area
Figure 4.8 Targeted Drug Delivery Devices for Biologics: Distribution by Status of Development and Target Therapeutic Area
Figure 4.9 Targeted Drug Delivery Devices for Biologics: Distribution by Type of Biologic Delivered
Figure 4.10 Targeted Drug Delivery Devices for Biologics: Distribution by Type of Therapy Delivered
Figure 4.11 Targeted Drug Delivery Devices for Biologics: Distribution by Route of Administration
Figure 4.12 Targeted Drug Delivery Device Developers: Distribution by Type of Stakeholder
Figure 4.13 Targeted Drug Delivery Device Developers: Distribution by Year of Establishment
Figure 4.14 Targeted Drug Delivery Device Developers (Industry Players): Distribution by Company Size
Figure 4.15 Targeted Drug Delivery Device Developers (Industry Players): Distribution by Location of Headquarters
Figure 4.16 Targeted Drug Delivery Device Developers (Non-Industry Players): Distribution by Location of Headquarters
Figure 6.1 Stem Cell Therapies for Neurological Disorders, Publication Analysis: Cumulative Trend by Year, 2015-2019
Figure 6.2 Stem Cell Therapies for Neurological Disorders, Grants Analysis: Cumulative Year-wise Trend, 2015-2020
Figure 6.3 Stem Cell Therapies for Neurological Disorders, Grants Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
Figure 6.4 Gene Therapies for Neurological Disorders, Publications Analysis: Cumulative Trend by Year, 2015-2019
Figure 6.5 Gene Therapies for Neurological Disorders, Grants Analysis: Cumulative Year-wise Trend, 2015-2020
Figure 6.6 Gene Therapies for Neurological Disorders, Grants Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
Figure 6.7 Stem Cell Therapies for Cardiovascular Disorders, Publications Analysis: Cumulative Trend by Year, 2015-2019
Figure 6.8 Stem Cell Therapies for Cardiovascular Disorders, Grants Analysis: Cumulative Year-wise Trend, 2015-2020
Figure 6.9 Stem Cell Therapies for Cardiovascular Disorders, Grants Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
Figure 6.10 Gene Therapies for Cardiovascular Disorders, Publications Analysis: Cumulative Trend by Year, 2015-2019
Figure 6.11 Gene Therapies for Cardiovascular Disorders, Grants Analysis: Cumulative Year-wise Trend, 2015-2020
Figure 6.12 Gene Therapies for Cardiovascular Disorders, Grants Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
Figure 6.13 Emerging Focus Area
Figure 6.14 Summary of R&D Activity
Figure 7.1 Stem Cell and Gene Therapy Clinical Trials: Distribution by Trial Registration Year
Figure 7.2 Stem Cell and Gene Therapy Clinical Trials: Distribution by Trial Phase
Figure 7.3 Stem Cell and Gene Therapy Clinical Trials: Distribution by Trial Status
Figure 7.4 Stem Cell and Gene Therapy Clinical Trials: Distribution by Type of Sponsor / Collaborator
Figure 7.5 Stem Cell and Gene Therapy Clinical Trials: Distribution by Type of Therapy
Figure 7.6 Stem Cell and Gene Therapy Clinical Trials: Distribution by Therapeutic Area
Figure 7.7 Stem Cell and Gene Therapy Clinical Trials: Distribution by Therapeutic Indication
Figure 7.8 Stem Cell and Gene Therapy Clinical Trials: Distribution by Route of Administration
Figure 7.9 Stem Cell and Gene Therapy Clinical Trials: Distribution by Trial Status and Trial Phase
Figure 7.10 Most Active Industry Players: Distribution by Number of Registered Stem Cell and Gene Therapy Clinical Trials
Figure 7.11 Most Active Non-Industry Players: Distribution by Number of Registered Stem Cell and Gene Therapy Clinical Trials
Figure 7.12 Stem Cell and Gene Therapy Clinical Trials: Distribution by Geographical Location
Figure 7.13 Stem Cell and Gene Therapy Clinical Trials: Distribution by Geographical Location and Trial Phase
Figure 7.14 Stem Cell and Gene Therapy Clinical Trials: Distribution by Geographical Location and Trial Status
Figure 7.15 Stem Cell and Gene Therapy Clinical Trials: Distribution by Geographical Location and Therapeutic Area
Figure 7.16 Stem Cell and Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Registration Year
Figure 7.17 Stem Cell and Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Phase
Figure 7.18 Stem Cell and Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Type of Therapy
Figure 7.19 Stem Cell and Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Therapeutic Area
Figure 7.20 Stem Cell and Gene Therapy Clinical Trials: Distribution by Patients Enrolled, Trial Status and Geographical Location
Figure 7.21 Stem Cell Therapy Clinical Trials: Distribution by Trial Registration Year
Figure 7.22 Stem Cell Therapy Clinical Trials: Distribution by Trial Phase
Figure 7.23 Stem Cell Therapy Clinical Trials: Distribution by Trial Status
Figure 7.24 Stem Cell Therapy Clinical Trials: Distribution by Type of Sponsor / Collaborator
Figure 7.25 Stem Cell Therapy Clinical Trials: Distribution by Therapeutic Area
Figure 7.26 Stem Cell Therapy Clinical Trials: Distribution by Route of Administration
Figure 7.27 Stem Cell Therapy Clinical Trials: Distribution by Trial Status and Trial Phase
Figure 7.28 Stem Cell Therapy Clinical Trials: Distribution by Geographical Location
Figure 7.29 Stem Cell Therapy Clinical Trials: Distribution by Geographical Location and Trial Phase
Figure 7.30 Stem Cell Therapy Clinical Trials: Distribution by Geographical Location and Trial Status
Figure 7.31 Stem Cell Therapy Clinical Trials: Distribution by Geographical Location and Therapeutic Area
Figure 7.32 Stem Cell Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Registration Year
Figure 7.33 Stem Cell Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Phase
Figure 7.34 Stem Cell Therapy Clinical Trials: Distribution by Patients Enrolled and Type of Therapy
Figure 7.35 Stem Cell Therapy Clinical Trials: Distribution by Patients Enrolled and Therapeutic Area
Figure 7.36 Stem Cell Therapy Clinical Trials: Distribution by Patients Enrolled, Trial Status and Geographical Location
Figure 7.37 Gene Therapy Clinical Trials: Distribution by Trial Registration Year
Figure 7.38 Gene Therapy Clinical Trials: Distribution by Trial Phase
Figure 7.39 Gene Therapy Clinical Trials: Distribution by Trial Status
Figure 7.40 Gene Therapy Clinical Trials: Distribution by Type of Sponsor / Collaborator
Figure 7.41 Gene Therapy Clinical Trials: Distribution by Therapeutic Area
Figure 7.42 Gene Therapy Clinical Trials: Distribution by Route of Administration
Figure 7.43 Gene Therapy Clinical Trials: Distribution by Trial Status and Trial Phase
Figure 7.44 Gene Therapy Clinical Trials: Distribution by Geographical Location
Figure 7.45 Gene Therapy Clinical Trials: Distribution by Geographical Location and Trial Phase
Figure 7.46 Gene Therapy Clinical Trials: Distribution by Geographical Location and Trial Status
Figure 7.47 Gene Therapy Clinical Trials: Distribution by Geographical Location and Therapeutic Area
Figure 7.48 Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Registration Year
Figure 7.49 Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Phase
Figure 7.50 Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Type of Therapy
Figure 7.51 Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Therapeutic Area
Figure 7.52 Gene Therapy Clinical Trials: Distribution by Patients Enrolled, Trial Status and Geographical Location
Figure 8.1 Likely Partner Analysis: Distribution by Company Size and Location of Headquarters of Stem Cell Therapy Developers
Figure 8.2 Likely Partner Analysis: Distribution by Company Size and Location of Headquarters of Gene Therapy Developers
Figure 9.1. Targeted Drug Delivery Devices Market for Biologics, Till 2030 (USD Million)
Figure 9.2 Device Forecast: Helix Biotherapeutic Delivery System, Till 2030 (Number of Units)
Figure 9.3 BCDA-01 Sales Forecast, Till 2030 (USD Million)
Figure 9.4 Device Forecast: HelixTM Biotherapeutic Delivery System, Till 2030 (Number of Units)
Figure 9.5 BCDA-02 Sales Forecast, Till 2030 (USD Million)
Figure 9.6 Renexus® Sales Forecast, Till 2030 (USD Million)
Figure 9.7 Device Forecast: SmartFlow® Neuro Ventricular Cannula, Till 2030 (Number of Units)
Figure 9.8 LYS-SAF302 Sales Forecast, Till 2030 (USD Million)
Figure 9.9 Cell-in-a-Box® Sales Forecast, Till 2030 (USD Million)
Figure 9.10 Device Forecast: Alcyone's MEMS Cannula, Till 2030 (Number of Units)
Figure 9.11 DNX-2401 Sales Forecast, Till 2030 (USD Million)
Figure 9.12 Device Forecast: Electro-Transfection Injection System, Till 2030 (Number of Units)
Figure 9.13 EYS606 Sales Forecast, Till 2030 (USD Million)
Figure 9.14 NTCELL® Sales Forecast, Till 2030 (USD Million)
Figure 9.15 Device Forecast: ImmunoPulse® IL-12, Till 2030 (Number of Units)
Figure 9.16 TAVO Sales Forecast, Till 2030 (USD Million)
Figure 9.17 Device Forecast: SmartFlow® Neuro Ventricular Cannula, Till 2030 (Number of Units)
Figure 9.18 VY-AADC02 Sales Forecast, Till 2030 (USD Million)
Figure 9.19 Targeted Drug Delivery Devices Market for Biologics, Till 2030: Distribution by Type of Device (USD Million)
Figure 9.20 Targeted Drug Delivery Devices Market for Biologics, Till 2030: Distribution by Target Organ (USD Million)
Figure 9.21 Targeted Drug Delivery Devices Market for Biologics: Market Attractiveness Analysis by Target Organ, 2026-2030
Figure 9.22. Targeted Drug Delivery Devices Market for Biologics, Till 2030: Distribution by Target Indication (USD Million)
Figure 9.23. Targeted Drug Delivery Devices Market for Biologics, Till 2030: Distribution by Target Therapeutic Area (USD Million)
Figure 9.24. Targeted Drug Delivery Devices Market for Biologics, Till 2030: Distribution by Type of Therapy Delivered (USD Million)
Figure 9.25 Targeted Drug Delivery Devices Market for Biologics, Till 2030: Distribution by Key Geographical Region (USD Million)
Figure 9.26. Targeted Drug Delivery Devices Market for Biologics in North America, Till 2030 (USD Million)
Figure 9.27. Targeted Drug Delivery Devices Market for Biologics in Europe, Till 2030 (USD Million)
Figure 9.28. Targeted Drug Delivery Devices Market for Biologics in Asia-Pacific, Till 2030 (USD Million)
Figure 10.1. Concluding Remarks: Current Market Landscape Summary
Figure 10.2. Concluding Remarks: Clinical Trial Analysis
Figure 10.3. Concluding Remarks: Likely Partner Analysis
Figure 10.4. Market Sizing and Opportunity Analysis
Table 4.1 Targeted Drug Delivery Devices for Biologics: List of Approved / Under Development Devices
Table 4.2 Targeted Drug Delivery Devices for Biologics: Information on Type of Biologic Delivered, Type of Therapy Delivered and Route of Administration
Table 4.3 Targeted Drug Delivery Devices for Biologics: Additional Information
Table 4.4 Targeted Drug Delivery Devices for Biologics: List of Developers
Table 5.1 Targeted Drug Delivery Devices for Biologics: List of Devices Profiled
Table 5.2 Alcyone MEMS Cannula (AMCTM): List / Details of Clinical Trials
Table 5.3 Bullfrog® Micro-Infusion Device: List / Details of Clinical Trials
Table 5.4 HelixTM Biotherapeutic Delivery System: List / Details of Clinical Trials
Table 5.5 Orbit Subretinal Delivery System: List / Details of Clinical Trials
Table 5.6 SmartFlow® Neuro Ventricular Cannula: List / Details of Clinical Trials
Table 5.7 Renexus®: List / Details of Clinical Trials
Table 6.1 Stem Cell Therapies for Neurological Disorders: List of Approved / Under Development Therapies
Table 6.2 Stem Cell Therapies for Neurological Disorders: List of Publications, 2015-2020
Table 6.3 Stem Cell Therapies for Neurological Disorders: List of Academic Grants, 2015-2020
Table 6.4 Gene Therapies for Neurological Disorders: List of Approved / Under Development Therapies
Table 6.5 Gene Therapies for Neurological Disorders: List of Publications, 2015-2020
Table 6.6 Gene Therapies for Neurological Disorders: List of Academic Grants, 2015-2020
Table 6.7 Stem Cell Therapies for Cardiovascular Disorders: List of Approved / Under Development Therapies
Table 6.8 Stem Cell Therapies for Cardiovascular Disorders: List of Publications, 2015-2020
Table 6.9 Stem Cell Therapies for Cardiovascular Disorders: List of Academic Grants, 2015-2020
Table 6.10 Gene Therapies for Cardiovascular Disorders: List of Approved / Under Development Therapies
Table 6.11 Gene Therapies for Cardiovascular Disorders: List of Publications, 2015-2020
Table 6.12 Gene Therapies for Cardiovascular Disorders: List of Academic Grants, 2015-2020
Table 8.1 Stem Cell Therapy Developers in North America: Most Likely Partners
Table 8.2 Stem Cell Therapy Developers in North America: Likely Partners
Table 8.3 Stem Cell Therapy Developers in North America: Less Likely Partners
Table 8.4 Stem Cell Therapy Developers in Europe: Most Likely Partners
Table 8.5 Stem Cell Therapy Developers in Europe: Likely Partners
Table 8.6 Stem Cell Therapy Developers in Europe: Less Likely Partners
Table 8.7 Stem Cell Therapy Developers in Asia-Pacific and Rest of the World: Most Likely Partners
Table 8.8 Stem Cell Therapy Developers in Asia-Pacific and Rest of the World: Likely Partners
Table 8.9 Stem Cell Therapy Developers in Asia-Pacific and Rest of the World: Less Likely Partners
Table 8.10 Gene Therapy Developers in North America: Most Likely Partners
Table 8.11 Gene Therapy Developers in North America: Likely Partners
Table 8.12 Gene Therapy Developers in North America: Less Likely Partners
Table 8.13 Gene Therapy Developers in Europe: Most Likely Partners
Table 8.14 Gene Therapy Developers in Europe: Likely Partners
Table 8.15 Gene Therapy Developers in Europe: Less Likely Partners
Table 8.16 Gene Therapy Developers in Asia-Pacific and Rest of the World: Most Likely Partners
Table 8.17 Gene Therapy Developers in Asia-Pacific and Rest of the World: Likely Partners
Table 8.18 Gene Therapy Developers in Asia-Pacific and Rest of the World: Less Likely Partners
Table 9.1 Targeted Drug Delivery Devices Market for Biologics: List of Forecasted Candidates
Table 9.2 BCDA-01: Target Patient Population
Table 9.3 BCDA-02: Target Patient Population
Table 9.4 Renexus®: Target Patient Population
Table 9.5 LYS-SAF302: Target Patient Population
Table 9.6 Cell-in-a-Box®: Target Patient Population
Table 9.7 DNX-2401: Target Patient Population
Table 9.8 EYS606: Target Patient Population
Table 9.9 NTCELL®: Target Patient Population
Table 9.10 TAVO: Target Patient Population
Table 9.11 VY-AADC02: Target Patient Population
Table 10.1 Targeted Drug Delivery Devices Market for Biologics: Key Takeaways
Table 11.1 Seraxis: Key Highlights
Table 11.2 Defymed: Key Highlights
Table 11.3 University of Texas at San Antonio: Key Highlights
Table 11.4 Massachusetts Institute of Technology: Key Highlights
Table 12.1 Targeted Drug Delivery Devices for Biologics: Distribution by Type of Device
Table 12.2 Targeted Drug Delivery Devices for Biologics: Distribution by Status of Development
Table 12.3 Targeted Drug Delivery Devices for Biologics: Distribution by Type of Device and Status of Development
Table 12.4 Targeted Drug Delivery Devices for Biologics: Distribution by Target Organ
Table 12.5 Targeted Drug Delivery Devices for Biologics: Distribution by Type of Device and Target Organ
Table 12.6 Targeted Drug Delivery Devices for Biologics: Distribution by Target Indication
Table 12.7 Targeted Drug Delivery Devices for Biologics: Distribution by Target Therapeutic Area
Table 12.8 Targeted Drug Delivery Devices for Biologics: Distribution by Status of Development and Target Therapeutic Area
Table 12.9 Targeted Drug Delivery Devices for Biologics: Distribution by Type of Biologic Delivered
Table 12.10 Targeted Drug Delivery Devices for Biologics: Distribution by Type of Therapy Delivered
Table 12.11 Targeted Drug Delivery Devices for Biologics: Distribution by Route of Administration
Table 12.12 Device Developers: Distribution by Type of Stakeholder
Table 12.13 Device Developers: Distribution by Year of Establishment
Table 12.14 Device Developers: Distribution by Company Size
Table 12.15 Device Developers (Industry Players): Distribution by Location of Headquarters
Table 12.16 Device Developers (Non-Industry Players): Distribution by Location of Headquarters
Table 12.17 Stem Cell Therapy for Neurological Disorders, Publications Analysis: Cumulative Trend by Year, 2015-2019
Table 12.18 Stem Cell Therapy for Neurological Disorders, Grants Analysis: Cumulative Year-wise Trend, 2015-2020
Table 12.19 Stem Cell Therapy for Neurological Disorders, Grants Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
Table 12.20 Gene Therapy for Neurological Disorders, Publications Analysis: Cumulative Trend by Year, 2015-2019
Table 12.21 Gene Therapy for Neurological Disorders, Grants Analysis: Cumulative Year-wise Trend, 2015-2020
Table 12.22 Gene Therapy for Neurological Disorders, Grants Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
Table 12.23 Stem Cell Therapy for Cardiovascular Disorders, Publications Analysis: Cumulative Trend by Year, 2015-2019
Table 12.24 Stem Cell Therapy for Cardiovascular Disorders, Grants Analysis: Cumulative Year-wise Trend, 2015-2020
Table 12.25 Stem Cell Therapy for Cardiovascular Disorders, Grants Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
Table 12.26 Gene Therapy for Cardiovascular Disorders, Publications Analysis: Cumulative Trend by Year, 2015-2019
Table 12.27 Gene Therapy for Cardiovascular Disorders, Grants Analysis: Cumulative Trend by Year, 2015-2020
Table 12.28 Gene Therapy for Cardiovascular Disorders, Grants Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
Table 12.29 Stem Cell and Gene Therapy Clinical Trials: Distribution by Trial Registration Year
Table 12.30 Stem Cell and Gene Therapy Clinical Trials: Distribution by Trial Phase
Table 12.31 Stem Cell and Gene Therapy Clinical Trials: Distribution by Trial Status
Table 12.32 Stem Cell and Gene Therapy Clinical Trials: Distribution by Type of Sponsor / Collaborator
Table 12.33 Stem Cell and Gene Therapy Clinical Trials: Distribution by Type of Therapy
Table 12.34 Stem Cell and Gene Therapy Clinical Trials: Distribution by Therapeutic Area
Table 12.35 Stem Cell and Gene Therapy Clinical Trials: Distribution by Therapeutic Indication
Table 12.36 Stem Cell and Gene Therapy Clinical Trials: Distribution by Route of Administration
Table 12.37 Stem Cell and Gene Therapy Clinical Trials: Distribution by Trial Status and Trial Phase
Table 12.38 Most Active Industry Players: Distribution by Number of Registered Stem Cell and Gene Therapy Clinical Trials
Table 12.39 Most Active Non-Industry Players: Distribution by Number of Registered Stem Cell and Gene Therapy Clinical Trials
Table 12.40 Stem Cell and Gene Therapy Clinical Trials: Distribution by Geographical Location
Table 12.41 Stem Cell and Gene Therapy Clinical Trials: Distribution by Geographical Location and Trial Phase
Table 12.42 Stem Cell and Gene Therapy Clinical Trials: Distribution by Geographical Location and Trial Status
Table 12.43 Stem Cell and Gene Therapy Clinical Trials: Distribution by Geographical Location and Therapeutic Area
Table 12.44 Stem Cell and Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Registration Year
Table 12.45 Stem Cell and Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Phase
Table 12.46 Stem Cell and Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Type of Therapy
Table 12.47 Stem Cell and Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Therapeutic Area
Table 12.48 Stem Cell Therapy Clinical Trials: Distribution by Trial Registration Year
Table 12.49 Stem Cell Therapy Clinical Trials: Distribution by Trial Phase
Table 12.50 Stem Cell Therapy Clinical Trials: Distribution by Trial Status
Table 12.51 Stem Cell Therapy Clinical Trials: Distribution by Type of Sponsor / Collaborator
Table 12.52 Stem Cell Therapy Clinical Trials: Distribution by Therapeutic Area
Table 12.53 Stem Cell Therapy Clinical Trials: Distribution by Therapeutic Indication
Table 12.54 Stem Cell Therapy Clinical Trials: Distribution by Route of Administration
Table 12.55 Stem Cell Therapy Clinical Trials: Distribution by Trial Status and Trial Phase
Table 12.56 Stem Cell Therapy Clinical Trials: Distribution by Geographical Location
Table 12.57 Stem Cell Therapy Clinical Trials: Distribution by Geographical Location and Trial Phase
Table 12.58 Stem Cell Therapy Clinical Trials: Distribution by Geographical Location and Trial Status
Table 12.59 Stem Cell Therapy Clinical Trials: Distribution by Geographical Location and Therapeutic Area
Table 12.60 Stem Cell Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Registration Year
Table 12.61 Stem Cell Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Phase
Table 12.62 Stem Cell Therapy Clinical Trials: Distribution by Patients Enrolled and Therapeutic Area
Table 12.63 Gene Therapy Clinical Trials: Distribution by Trial Registration Year
Table 12.64 Gene Therapy Clinical Trials: Distribution by Trial Phase
Table 12.65 Gene Therapy Clinical Trials: Distribution by Trial Status
Table 12.66 Gene Therapy Clinical Trials: Distribution by Type of Sponsor / Collaborator
Table 12.67 Gene Therapy Clinical Trials: Distribution by Therapeutic Area
Table 12.68 Gene Therapy Clinical Trials: Distribution by Therapeutic Indication
Table 12.69 Gene Therapy Clinical Trials: Distribution by Route of Administration
Table 12.70 Gene Therapy Clinical Trials: Distribution by Trial Status and Trial Phase
Table 12.71 Gene Therapy Clinical Trials: Distribution by Geographical Location
Table 12.72 Gene Therapy Clinical Trials: Distribution by Geographical Location and Trial Phase
Table 12.73 Gene Therapy Clinical Trials: Distribution by Geographical Location and Trial Status
Table 12.74 Gene Therapy Clinical Trials: Distribution by Geographical Location and Therapeutic Area
Table 12.75 Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Registration Year
Table 12.76 Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Phase
Table 12.77 Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Therapeutic Area
Table 12.78 Targeted Drug Delivery Devices Market for Biologics, Conservative, Base and Optimistic Scenarios, Till 2030 (USD Million)
Table 12.79 Device Forecast: HelixTM Biotherapeutic Delivery System, Conservative, Base and Optimistic Scenarios, Till 2030 (Number of Units)
Table 12.80 BCDA-01 Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2030 (USD Million)
Table 12.81 Device Forecast: HelixTM Biotherapeutic Delivery System, Conservative, Base and Optimistic Scenarios, Till 2030 (Number of Units)
Table 12.82 BCDA-02 Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2030 (USD Million)
Table 12.83 Renexus® Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2030 (USD Million)
Table 12.84 Device Forecast: SmartFlow® Neuro Ventricular Cannula, Conservative, Base and Optimistic Scenarios, Till 2030 (Number of Units)
Table 12.85 LYS-SAF302 Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2030 (USD Million)
Table 12.86 Cell-in-a-Box® Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2030 (USD Million)
Table 12.87 Device Forecast: Alcyone's MEMS Cannula, Conservative, Base and Optimistic Scenarios, Till 2030 (Number of Units)
Table 12.88 DNX-2401 Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2030 (USD Million)
Table 12.89 Device Forecast: Electro-Transfection Injection System, Conservative, Base and Optimistic Scenarios, Till 2030 (Number of Units)
Table 12.90 EYS606 Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2030 (USD Million)
Table 12.91 NTCELL® Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2030 (USD Million)
Table 12.92 Device Forecast: ImmunoPulse® IL-12, Conservative, Base and Optimistic Scenarios, Till 2030 (Number of Units)
Table 12.93 TAVO Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2030 (Number of Units)
Table 12.94 Device Forecast: SmartFlow® Neuro Ventricular Cannula, Conservative, Base and Optimistic Scenarios, Till 2030 (Number of Units)
Table 12.95 VY-AADC02 Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2030 (USD Million)
Table 12.96 Targeted Drug Delivery Devices Market for Biologics, Conservative, Base and Optimistic Scenarios, Till 2030: Distribution by Type of Device, (USD Million)
Table 12.97 Targeted Drug Delivery Devices Market for Biologics, Conservative, Base and Optimistic Scenarios, Till 2030: Distribution by Target Organ, (USD Million)
Table 12.98 Targeted Drug Delivery Devices Market for Biologics, Conservative, Base and Optimistic Scenarios, Till 2030: Distribution by Target Indication, (USD Million)
Table 12.99 Targeted Drug Delivery Devices Market for Biologics, Conservative, Base and Optimistic Scenarios, Till 2030: Distribution by Target Therapeutic Area, (USD Million)
Table 12.100 Targeted Drug Delivery Devices Market for Biologics, Conservative, Base and Optimistic Scenarios, Till 2030: Distribution by Type of Therapy Delivered, (USD Million)
Table 12.101 Targeted Drug Delivery Devices Market for Biologics, Conservative, Base and Optimistic Scenarios, Till 2030: Distribution by Key Geographical Regions, 2025 and 2030
Table 12.102 Targeted Drug Delivery Devices Market for Biologics in North America, Conservative, Base and Optimistic Scenarios, Till 2030 (USD Million)
Table 12.103 Targeted Drug Delivery Devices Market for Biologics in Europe, Conservative, Base and Optimistic Scenarios, Till 2030 (USD Million)
Table 12.104 Targeted Drug Delivery Devices Market for Biologics in Asia-Pacific, Conservative, Base and Optimistic Scenarios, Till 2030 (USD Million)
The following companies and organizations have been mentioned in the report.
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
YOU MAY ALSO LIKE
SUBSCRIBE TO INDUSTRY UPDATES